rGel-Adn-IGF1R

rGel-Adn-IGF1R is a recombinant fusion toxin consisting of a ribosome-inactivating protein, recombinant gelonin (rGel), fused to an Adnectin (Adn-IGF1R) that specifically targets the insulin-like growth factor 1 receptor (IGF1R). Developed through a collaboration between MD Anderson Cancer Center and Adnexus (a Bristol Myers Squibb company), this agent is designed to treat IGF1R-overexpressing malignancies such as pancreatic and breast cancers. The Adnectin portion, derived from human fibronectin, binds with high affinity to the extracellular domain of IGF1R, facilitating the rapid internalization of the construct into tumor cells. Once inside, the rGel component acts as an N-glycosidase to irreversibly inactivate the 28S ribosomal RNA, thereby inhibiting protein synthesis and inducing apoptosis. In preclinical models, rGel-Adn-IGF1R has demonstrated significantly higher potency compared to free rGel or the Adnectin alone, and it effectively inhibits IGF1R and AKT phosphorylation.

Other names

rGelonin-Adnectin-IGF1R fusion proteinrGelonin-Adnectin-IGF-1R fusion proteinrGelonin-Adnectin-IGF 1R fusion proteinrGel-Adn-IGF1R constructrGel-Adn-IGF-1R constructrGel-Adn-IGF 1R construct